Early therapy with basal insulin does not reduce cardiovascular outcomes in dysglycemic patients


Early initiation of basal insulin did not impact cardiovascular outcomes compared to standard management of glucose in patients with type 2 diabetes or elevated fasting glucose with cardiovascular risk factors.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.